EKF Diagnostics (EKF) Share Price, News & Analysis

Company Overview

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Key Stats

• Today's Range: 24.60 to 25
• 50-Day Range: 24.60 to 27
• 52-Week Range: 22 to 32
• Volume: 372,528 shs
• Average Volume: 328,396 shs
• Market Capitalization: £107.49 million
• P/E Ratio: 53.19
• Dividend Yield: 4.65%
• Price Target: GBX 35
• Consensus Rating: Buy

EKF Diagnostics Stock Analysis - MarketRank™

EKF Diagnostics scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

EKF Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

EKF Diagnostics has a consensus price target of GBX 35, representing about 40.0% upside from its current price of GBX 25.

Amount of Analyst Coverage

EKF Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of EKF Diagnostics is 53.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of EKF Diagnostics is 53.19, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.18.

Price to Book Value per Share Ratio

EKF Diagnostics has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EKF.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

EKF Diagnostics is a leading dividend payer. It pays a dividend yield of 4.65%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

EKF Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.67

News Sentiment

EKF Diagnostics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for EKF Diagnostics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, EKF Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.04% of the stock of EKF Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.17% of the stock of EKF Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 3/24/2026
• Today: 8/20/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:EKF
• CIK: N/A
• Web: www.ekfdiagnostics.com
• Phone: +44-29-20710570
• Fax: N/A
• Employees: 356
• Year Founded: N/A

Price Target and Rating

• Average Price Target for EKF Diagnostics: GBX 35
• High Price Target: GBX 35
• Low Price Target: GBX 35
• Potential Upside/Downside: +40.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.47
• Trailing P/E Ratio: 53.19
• Forward P/E Ratio: 10.88
• P/E Growth: N/A
• Net Income: £4.68 million
• Net Margins: 4.12%
• Pretax Margin: N/A
• Return on Equity: 3.01%
• Return on Assets: 5.27%

Debt

• Debt-to-Equity Ratio: 2.01
• Current Ratio: 4.16
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: £51.56 million
• Price / Sales: 2.08
• Cash Flow: GBX 2.35 per share
• Price / Cash Flow: 10.64
• Book Value: GBX 15.41 per share
• Price / Book: 1.62

Miscellaneous

• Outstanding Shares: 429,973,000
• Free Float: N/A
• Market Cap: £107.49 million
• Optionable: Not Optionable
• Beta: 0.50